Robert M. A. Hirschfeld
and Siegfried Kasper
().
A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder.
The International Journal of Neuropsychopharmacology,
7
,
pp 507-522
doi:10.1017/S1461145704004651
Aygun Ertugrul
and Herbert Y. Meltzer
().
Antipsychotic drugs in bipolar disorder.
The International Journal of Neuropsychopharmacology,
6
,
pp 277-284
doi:10.1017/S1461145703003560
JING DU,
JORGE QUIROZ,
PEIXIONG YUAN,
CARLOS ZARATE
and HUSSEINI K. MANJI
().
Bipolar disorder: involvement of signaling cascades and AMPA receptor trafficking at synapses.
Neuron Glia Biology,
1
,
pp 231-243
doi:10.1017/S1740925X05000098
Mauricio Tohen
and Daniel Yen Lin
().
Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder.
Progress in Neurotherapeutics and Neuropsychopharmacology,
2
,
pp 225-238
doi:10.1017/S1748232106000164
Alessandro Serretti,
Paola Artioli,
Cristina Lorenzi,
Adele Pirovano,
Viviana Tubazio
and Raffaella Zanardi
().
The C(–1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings.
The International Journal of Neuropsychopharmacology,
7
,
pp 453-460
doi:10.1017/S1461145704004687
David E. Kemp,
Keming Gao,
David J. Muzina,
Prashant Gajwani
and Joseph R. Calabrese
().
Trial-Based Advances in the Treatment of Bipolar Depression.
Progress in Neurotherapeutics and Neuropsychopharmacology,
2
,
pp 193-212
doi:10.1017/S1748232106000140
Stephen Pereira,
Wolfgang Fleischhacker
and Michael Allen
().
Management of behavioural emergencies.
Journal of Psychiatric Intensive Care,
2
,
pp 71-83
doi:10.1017/S1742646407000325
Nuria Cruz,
Jose Sanchez-Moreno,
Ferran Torres,
Jose Manuel Goikolea,
Marc ValentÃ
and Eduard Vieta
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
The International Journal of Neuropsychopharmacology,
Published online by Cambridge University Press 19 Dec 2006
doi:10.1017/S1461145709990344
E. Ephraim
and R. Prettyman
().
Attitudes of old age psychiatrists in England and Wales to the use of mood stabilizer drugs.
International Psychogeriatrics,
21
,
pp 576-580
doi:10.1017/S1041610209008667